Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03683589 · ClinicalTrials.gov registry record
De Novo Lipogenesis in Severity of NAFLD
A clinical trial, sponsored by University of Missouri-Columbia.
- Completed
- Registry status
- 49
- Enrollment target
NCT03683589: Completed study, sponsored by University of Missouri-Columbia.
NCT03683589 is a clinical trial that has completed, run by University of Missouri-Columbia. The registered enrollment target is 49 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03683589 has completed, sponsored by University of Missouri-Columbia.
- COMPLETED
- Registry status
- 49 participants
- Enrollment target
Study Summary
NAFLD is the most prevalent liver disease in the U.S., and there is a serious need to understand its progression to the advanced state, nonalcoholic steatohepatitis (NASH). Previous studies has shown that elevated de novo lipogenesis (DNL) is the unique, early event distinguishing patients with NAFLD from equally-obese subjects with low IHTG. The purpose of this study is to directly by measure DNL in human liver tissue and comparing it to liver histological scores from patient biopsies.
Primary Outcome
DNL will be measured directly in the liver biopsies
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2019-02-01 |
| Est. Completion | 2020-07-31 |
What the finished NCT03683589 record still lists
NCT03683589 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 49 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT03683589 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03683589 about?
NCT03683589 is a clinical study titled "De Novo Lipogenesis in Severity of NAFLD". NAFLD is the most prevalent liver disease in the U.S., and there is a serious need to understand its progression to the advanced state, nonalcoholic steatohepatitis (NASH). Previous studies has shown that elevated de novo lipogenesis (DNL) is the unique, early event distinguishing patients with NAFL...
What is the current status of trial NCT03683589?
This trial is currently completed. The enrollment target is 49 participants. The study started on 2019-02-01. Estimated completion is 2020-07-31.
Who is sponsoring clinical trial NCT03683589?
This trial is sponsored by University of Missouri-Columbia, which has 291 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02704858 · 49 participants · Phase 1
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
- NCT03516708 · 49 participants · Phase 1
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
- NCT03692429 · 49 participants · Phase 1
alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
- NCT04329494 · 49 participants · Phase 1
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI